| pubmed-article:12443784 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12443784 | lifeskim:mentions | umls-concept:C1257890 | lld:lifeskim |
| pubmed-article:12443784 | lifeskim:mentions | umls-concept:C1323274 | lld:lifeskim |
| pubmed-article:12443784 | lifeskim:mentions | umls-concept:C0038477 | lld:lifeskim |
| pubmed-article:12443784 | lifeskim:mentions | umls-concept:C1999216 | lld:lifeskim |
| pubmed-article:12443784 | lifeskim:mentions | umls-concept:C0392747 | lld:lifeskim |
| pubmed-article:12443784 | lifeskim:mentions | umls-concept:C1554963 | lld:lifeskim |
| pubmed-article:12443784 | lifeskim:mentions | umls-concept:C0249363 | lld:lifeskim |
| pubmed-article:12443784 | lifeskim:mentions | umls-concept:C0965832 | lld:lifeskim |
| pubmed-article:12443784 | pubmed:dateCreated | 2002-11-21 | lld:pubmed |
| pubmed-article:12443784 | pubmed:abstractText | A series of analogues of the potent peptide deformylase (PDF) inhibitor BB-3497 containing alternative metal binding groups was synthesised. Enzyme inhibition and antibacterial activity data for these compounds revealed that the bidentate hydroxamic acid and N-formyl hydroxylamine structural motifs represent the optimum chelating groups on the pseudopeptidic BB-3497 backbone. | lld:pubmed |
| pubmed-article:12443784 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12443784 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12443784 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12443784 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12443784 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12443784 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12443784 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12443784 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12443784 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12443784 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12443784 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12443784 | pubmed:author | pubmed-author:BeckettR... | lld:pubmed |
| pubmed-article:12443784 | pubmed:author | pubmed-author:ThomasWayneW | lld:pubmed |
| pubmed-article:12443784 | pubmed:author | pubmed-author:ClementsJohn... | lld:pubmed |
| pubmed-article:12443784 | pubmed:author | pubmed-author:SmithHelen... | lld:pubmed |
| pubmed-article:12443784 | pubmed:author | pubmed-author:DoelSheilaS | lld:pubmed |
| pubmed-article:12443784 | pubmed:author | pubmed-author:EastStephen... | lld:pubmed |
| pubmed-article:12443784 | pubmed:author | pubmed-author:LaunchburySte... | lld:pubmed |
| pubmed-article:12443784 | pubmed:author | pubmed-author:PrattLisa MLM | lld:pubmed |
| pubmed-article:12443784 | pubmed:author | pubmed-author:SpavoldZoë... | lld:pubmed |
| pubmed-article:12443784 | pubmed:author | pubmed-author:ToddRichard... | lld:pubmed |
| pubmed-article:12443784 | pubmed:author | pubmed-author:WhittakerMark... | lld:pubmed |
| pubmed-article:12443784 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12443784 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12443784 | pubmed:pagination | 3595-9 | lld:pubmed |
| pubmed-article:12443784 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:12443784 | pubmed:articleTitle | Structure-activity relationships of the peptide deformylase inhibitor BB-3497: modification of the metal binding group. | lld:pubmed |
| pubmed-article:12443784 | pubmed:affiliation | British Biotech Pharmaceuticals Limited, Watlington Road, Oxford OX4 6LY, UK. | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:12443784 | lld:chembl |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12443784 | lld:pubmed |
